Literature DB >> 35106880

Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.

Harriet de Wit1, Hanna M Molla1, Anya Bershad2, Michael Bremmer1, Royce Lee1.   

Abstract

The resurgence of interest in using psychedelic drugs, including lysergic acid diethylamide (LSD), in psychiatry has drawn attention to the medically unsupervised practice of 'microdosing'. Thousands of users claim that very low doses of LSD, taken at 3-4-day intervals, improve mood and cognitive function., However, few controlled studies have described the effects of the drug when taken in this way. Here, in a double-blind controlled study, we studied the effects of four repeated doses of LSD tartrate (13 or 26 μg) or placebo, administered to healthy adults at 3-4 day intervals, on mood, cognitive performance and responses to emotional tasks. Participants were randomly assigned to one of three drug conditions: placebo (N = 18), 13 μg LSD (N = 19), or 26 μg LSD (N = 19). They attended four 5-hour drug-administration sessions separated by 3-4 days, followed by a drug-free follow-up session 3-4 days after the last session. LSD (26 μg) produced modest subjective effects including increased ratings of 'feeling a drug effect' and both stimulant-like and LSD-like effects, but the drug did not improve mood or affect performance on psychomotor or most emotional tasks. No residual effects were detected on mood or task performance on the drug-free follow-up session. We conclude that within the context of a controlled setting and a limited number of administrations, repeated low doses of LSD are safe, but produce negligible changes in mood or cognition in healthy volunteers.
© 2022 Society for the Study of Addiction.

Entities:  

Keywords:  LSD; behavior; cognition; microdosing; mood; psychopharmacology

Mesh:

Substances:

Year:  2022        PMID: 35106880     DOI: 10.1111/adb.13143

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  2 in total

1.  Psychedelic microdosing hits a rough patch in clinical trials.

Authors:  Benjamin Plackett
Journal:  Nature       Date:  2022-09       Impact factor: 69.504

2.  How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Authors:  Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2022-03-29       Impact factor: 4.415

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.